19 results on '"Koschmieder, Steffen"'
Search Results
2. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
3. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
4. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
5. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
6. Second versus first wave of COVID-19 in patients with MPN
7. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
8. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
9. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
10. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
11. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
12. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
13. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
14. Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
15. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita
16. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
17. Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
18. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
19. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.